The state of t

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re P	ratent Application of	MAIL STOP SEQUENCE			
Tanel ¹	Tenson et al. (0C1 1 0 1006 ()	Group Art Unit: Unassigned			
Application No.: 10/531,870 Examiner: Unassigned					
Filing [Date: April 19, 2005	Confirmation No.: 5979			
Title:	SELECTION SYSTEM CONTAINING NON-ANTIBIOTIC RESISTANCE SELECTION MARKER)				
RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS AND PRELIMINARY AMENDMENT TRANSMITTAL LETTER					
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
Sir:					
Enclosed is a Response to Notice to Comply with Sequence Listing Requirements And Preliminary Amendment for the above-identified patent application.					
	A Petition for Extension of Time is enclosed.				
	Terminal Disclaimer(s) and the \$\infty\$ \$ 65 \$\infty\$ \$ 130 fee per Disclaimer due under 37 C.F.R. \§ 1.20(d) are enclosed.				
	Also enclosed is/are: 1) Paper Copy of Substitute Sequence Listing, 2) a diskette containing the computer readable form (CRF) of the Sequence Listing, 3) a Declaration Pursuant to 37 C.F.R. §§ 1.821-1.825, and 4) Copy of Notice to Comply mailed on August 11, 2006.				
	Small entity status is hereby claimed.				
	Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the \$\square\$ \$ 395 \$\square\$ \$ 790 fee due under 37 C.F.R. § 1.17(e).				
	Applicant(s) requests that any previously unentered after final amendments <u>not</u> be entered. Continued examination is requested based on the enclosed documents identified above				

Applicant(s) requests suspension of action by the Office until at least

, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i)

is enclosed.

Applicant(s) previously submitted ___ continued examination is requested.

	A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.
\boxtimes	No additional claim fee is required.
	An additional claim fee is required, and is calculated as shown below:

AMENDED CLAIMS						
	No. of Claims	Highest No. of Claims Previously Paid For	Extra Claims	Rate	Additio	nal Fee
Total Claims	22	22	0	x \$ 50 (1202)	\$	0
Independent Claims	9	9	0	x \$ 200 (1201)		0
☐ If Amendment adds multiple dependent claims, add \$ 360 (1203)						0
Total Claim Amendment Fee					\$	0
☐ Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee						0
TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT					\$	0

	Charge	to Deposit Account No. 02-48	00 for the fee due.
	A check in the amount of	is enclosed	for the fee due.
	Charge	to credit card for the fee due.	Form PTO-2038 is attached.
\boxtimes	37 C.F.R. §§ 1.16, 1.17 a	thorized to charge any approp and 1.20(d) and 1.21 that may b at, to Deposit Account No. 02-4	pe required by this paper, and

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date October 10, 2006

Susan M. Dadie

Registration No. 40373

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620



Date Mailed: 08/11/2006

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addres: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspio.gov

ATTY. DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO. 010315-224 Tanel Tenson 10/531,870 INTERNATIONAL APPLICATION NO. PCT/FI04/00540 I.A. FILING DATE PRIORITY DATE 21839 09/15/2003 **BUCHANAN, INGERSOLL & ROONEY** 09/15/2004 **BUOHANAN INGERSOLL & ROONEY PC POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404 CONFIRMATION NO. 5979** 1 FORMALITIES LETTER 2000000019977896*

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

JOHN L ANDERSON

URGENT

Telephone: (703) 308-9140 EXT 211

1010315-000224 WCR/SMD SPOURNCE Liding Due 10-11-06

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/531,870	PCT/FI04/00540	010315-224

FORM PCT/DO/EO/922 (371 Formalities Notice)